Latest Reports

GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

The global non-alcoholic steatohepatitis (NASH) biomarker market is projected to register a CAGR of 20.65% by 2028, generating a revenue of $3545.9 million. The base year considered for the market study is 2020, and the forecast years are from 2021 to 2028. Non-alcoholic steatohepatitis (NASH) is a destructive form of non-alcoholic fatty liver disease (NAFLD) and often progress to more severe disorders, such as cirrhosis and hepatocellular carcinoma. GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST... Read more

ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

The Asia Pacific non-alcoholic steatohepatitis (NASH) biomarker market is estimated to project a CAGR of 23.00% during the forecast period, 2021-2028. The enhanced healthcare infrastructure, improving economic conditions, surging diagnosis rates, and the surging prevalence of NASH are projected to drive the market growth. China, Australia & New Zealand, Japan, Indonesia, Vietnam, South Korea, Thailand, India, and Rest of Asia Pacific, are assessed for the Asia Pacific non-alcoholic steatohepatitis (NASH) biomarker market growth analysis. ASIA PACIFIC... Read more

EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

The Europe non-alcoholic steatohepatitis (NASH) biomarker market is set to project a CAGR of 19.55% during the forecast period, 2021-2028. The increasing prevalence of NASH, the rising treatment awareness, the availability of technologically advanced diagnosis devices, and the growing aging population are set to drive the market growth. The Europe non-alcoholic steatohepatitis (NASH) biomarker market growth analysis includes the assessment of the United Kingdom, France, Poland, Russia, Italy, Germany, Belgium, and Rest of Europe. EUROPE NON-ALCOHOLIC... Read more

NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

The North America non-alcoholic steatohepatitis (NASH) biomarker market is expected to grow with a CAGR of 20.02%, during the forecast years of 2021 to 2028. The region’s market growth is mainly attributable to the increasing prevalence of obesity and diabetes, the early diagnosis of NASH, the expected launch of pipeline molecules, and favorable reimbursements in the healthcare infrastructure. The North America non-alcoholic steatohepatitis (NASH) biomarker market growth is assessed by evaluating the United States and... Read more

UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2026

The United States non-alcoholic steatohepatitis (NASH) biomarker market is anticipated to register a CAGR of 20.70% over the forecast period. The country’s market growth is facilitated by the surging prevalence of non-alcoholic fatty liver disease and the increasing numbers of obese patients. The base year considered for the market study is 2020, and the forecast years are from 2021 to 2026. The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing annually, in the United States,... Read more